From Self-sufficiency
Jump to: navigation, search
Systematic (IUPAC) name
N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin- 1-amine
Clinical data
  • None assigned
Routes of
Legal status
Legal status
  • Investigational
Pharmacokinetic data
Bioavailability High
Metabolism Extensive hepatic metabolism (mostly CYP3A4-mediated)[1]
Biological half-life 4.6 ± 1.1 h[1]
Excretion Fecal and renal[1]
CAS Number 212141-54-3
ATC code none
PubChem CID 151194
ChemSpider 133257
Chemical data
Formula C20H15ClN4
Molar mass 346.813 g·mol−1[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Vatalanib (INN, codenamed PTK787 or PTK/ZK) is a small molecule protein kinase inhibitor that inhibits angiogenesis. It is being studied as a possible treatment for several types of cancer, particularly cancer that is at an advanced stage or has not responded to chemotherapy. Vatalanib is orally active, that is, it is effective when taken by mouth.

Vatalanib is being developed by Bayer Schering and Novartis. It inhibits all known VEGF receptors, as well as platelet-derived growth factor receptor-beta and c-kit, but is most selective for VEGFR-2.[1][2][3][4]


Vatalanib was discovered through high-throughput screening.[2] It has been extensively investigated in Phase I, II and III clinical trials.[1][4] Two large, randomized controlled Phase III trials have studied the effect of adding vatalanib to the FOLFOX chemotherapy regimen in people with metastatic colorectal cancer: CONFIRM-1, whose participants had not yet received any treatment for their cancer; and CONFIRM-2, in which participants had received first-line treatment with irinotecan and fluoropyrimidines. Vatalanib produced no significant improvement in overall survival (the primary endpoint of the studies), although it did significantly increase progression-free survival in CONFIRM-2.[4] Both trials found that progression-free survival was improved in people with high levels of lactate dehydrogenase, an enzyme used as a marker of tissue breakdown; the reasons for and implications of this difference are still unclear.[4][5]

Adverse effects

The adverse effects of vatalanib appear similar to those of other VEGF inhibitors. In the CONFIRM trials, the most common side effects were high blood pressure, gastrointestinal upset (diarrhea, nausea, and vomiting), fatigue, and dizziness.[4]


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links

  1. 1.0 1.1 1.2 1.3 1.4 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  2. 2.0 2.1 Mariani SM (2004). "Antiangiogenesis cocktails—stirred or shaken?". Medscape General Medicine. 6 (4): 21. PMC 1480579Freely accessible. PMID 15775848.  Retrieved on October 29, 2008.
  3. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  4. 4.0 4.1 4.2 4.3 4.4 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  5. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.